Active	Status	Sponsor type	Region	Phase	Filter
14 Active 0 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Gordon, Peter M
CASSIOPEIA, NCT03876769 / 2017-002116-14: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients Jan 2025 - Dec 2025: Data from CASSIOPEIA trial for 1L acute ALL	Active, not recruiting	2	121	Europe, Canada, US	CTL019	Novartis Pharmaceuticals, Children's Oncology Group	B-Cell Acute Lymphoblastic Leukemia	10/27	10/27
Flagg, Aron
CASSIOPEIA, NCT03876769 / 2017-002116-14: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients Jan 2025 - Dec 2025: Data from CASSIOPEIA trial for 1L acute ALL	Active, not recruiting	2	121	Europe, Canada, US	CTL019	Novartis Pharmaceuticals, Children's Oncology Group	B-Cell Acute Lymphoblastic Leukemia	10/27	10/27
Koppes, Mollie
CASSIOPEIA, NCT03876769 / 2017-002116-14: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients Jan 2025 - Dec 2025: Data from CASSIOPEIA trial for 1L acute ALL	Active, not recruiting	2	121	Europe, Canada, US	CTL019	Novartis Pharmaceuticals, Children's Oncology Group	B-Cell Acute Lymphoblastic Leukemia	10/27	10/27
Rahrig, April
CASSIOPEIA, NCT03876769 / 2017-002116-14: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients Jan 2025 - Dec 2025: Data from CASSIOPEIA trial for 1L acute ALL	Active, not recruiting	2	121	Europe, Canada, US	CTL019	Novartis Pharmaceuticals, Children's Oncology Group	B-Cell Acute Lymphoblastic Leukemia	10/27	10/27